A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2012
This article has no abstract
Epistemonikos ID: da9a2885403ef994a956945c3a3e5b81c78ce2bf
First added on: Feb 05, 2025